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 Abstract  
This study investigates the application of melt extrusion for the development of an oral retard 
formulation with a precise drug release over time. Since adjusting the formulation appears to be of 
the utmost importance in achieving the desired drug release patterns, different formulations of 
laminar extrudates were prepared according to the principles of Experimental Design, using a 
design for mixtures to assess the influence of formulation composition on the in vitro drug release 
from the extrudates after 1 h and after 8 h. The effect of each component on the two response 
variables was also studied.  
Ternary mixtures of theophylline (model drug), monohydrate lactose and microcrystalline wax (as 
thermoplastic binder) were extruded in a lab scale vertical ram extruder in absence of solvents at a 
temperature below the melting point of the binder (so that the crystalline state of the drug could be 
maintained), through a rectangular die to obtain suitable laminar systems.  
Thanks to the desirability approach and a reliability study for ensuring the quality of the 
formulation, a very restricted optimal zone was defined within the experimental domain. Among the 
mixture components, the variation of microcrystalline wax content played the most significant role 
in overall influence on the in vitro drug release. The formulation theophylline:lactose:wax, 57:14:29 
(by weight), selected based on the desirability zone, was subsequently used for in vivo studies. The 
plasma profile, obtained after oral administration of the laminar extruded system in hard gelatine 
capsules, revealed the typical trend of an oral retard formulation.  
The application of the mixture experimental design associated to a desirability function permitted to 
optimize the extruded system and to determine the composition space that ensures final product 
quality.  
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1. Introduction 
Melt extrusion is a relatively recent solvent-free pharmaceutical processing technique applicable to 
both immediate release and sustained release dosage forms (Breitenbach, 2002; Douroumis , 2012). 
During the process, the mixture of thermoplastic binder, excipients and APIs are fed into the heated 
barrel, and extruded through the die attached at the end of the barrel (McGinity et al. 2007). The 
physical shape of the final product depends on the geometrical design of the die, obtaining e.g. 
cylinders, pipes, laminates, helices or films. In literature, both hollow and solid cylinders are the 
most studied shape of extrudates (Mehuys et al., 2004; Michalk et al. 2008), even though several 
authors have investigated the opportunity to change the shape (and hence the specific surface area) 
to tailor the attributes of the final system (e.g. drug release). Conversely laminar extrudates, being 
the most “obvious” shape and easiest to produce have been poorly investigated. To our best 
knowledge, rectangular dies are largely employed in the production of films but the only example of 
laminar extrudates reported in the literature is that of Pinto and coworkers (Oliveira et al., 2013). 
These authors have recently successfully produced such kind of extrudates using lipid-based 
excipients as carriers in absence of solvents and at ambient temperature. Yet, laminar extrudates 
have a great potential due to their high versatility being suitable for oral, buccal or topical 
administration. Furthermore, extrudates can be easily cut in different sizes allowing the convenient 
adjustment of the drug dose. Finally, this shape is suitable as a final dosage form, as well as to be 
filled in hard gelatine capsules (Müllers et al., 2013).  
The aim of the present investigation is to produce, in a lab scale vertical ram extruder, thin laminar 
extrudates (7.5x0.5x5 mm) with a targeted in vitro release of theophylline (model drug), ranging 
from 35% after 1 h and 75% after 8 h (Table 1), with the final purpose of producing a retard 
formulation for oral administration. The choice of thin laminar extrudates was also based on 
previous studies dealing with the relationship among surface area and drug release in 3 different 
helical shapes of extrudates (having 2, 3 and 4 blades)  (Hasa et al. 2011), and previous experiences 
with bi-layered cylindrical co-extrudate (Quintavalle et al., 2008). In this case, in order to ensure a 
successful formulation development, the design of experiments (DoE) principles were adopted to 
explore the composition space of the formulation. DoE is one of the most important area in drug 
development. Design and analysis of experiments are considered useful tools for really optimizing 
the process performance, identifying interactions among process variables, and reducing the process 
variation that can affect the quality of the output. DoE methodology can be applied in process 
development and improvement: screening DoE may be used for process parameter screening and 
statistical DoE for process parameter range determination. 
In particular, in this study to better ensure the desired product quality, the influence of formulation 
factors was analysed by developing quantitative regression models. Being the examined factors 
ingredients of a formulation, their amount cannot be varied independently, since their proportions 
sum up to 100%. Thus an experimental design for mixtures (Voinovich et al., 2009) was employed. 
This strategy has been previously applied to the preparation of hot melt extruded systems by 
Rambali et al., (2003) and recently by Djuris et al. (2013). To go into more details, several ternary 
mixtures (composed of theophylline, lactose and wax) according to an experimental design for 
mixtures were prepared and subjected to melt extrusion, and the influence of formulation 
composition on the in vitro drug release from such extrudates (after 1 h, experimental response Y1 
and after 8 h, Y2) was estimated. The experimental design for mixtures was hence associated to a 
desirability function, to optimize the extruded system. Inside the composition zone defined by 
desirability function one formulation was selected for in vivo studies and hence administered orally 
in hard gelatine capsules to healthy volunteers. Finally, the in vivo performance was studied by 
performing the pharmacokinetic analysis.  
 
2. Materials and methods 
2.1. Materials 
Anhydrous theophylline (theo), with a particle mean diameter (±S.D.) of 56 (±18) µm, was obtained 
from Polichimica s.r.l. (Bologna, Italy). Monohydrate lactose Flowlac
®
100-Meggle (lac) (having 
the following particle size distribution: <32 µm ≤ 10%, <100 µm ≤ 20-45%, <200 µm ≤ 80%) was a 
gift from Faravelli (Milan, Italy). Microcrystalline wax (or paraffinic wax, complex blends of 
mineral hydrocarbon waxes marketed as Paracera P, wax), with a particle mean diameter (±S.D.) of  
204 (±95) μm and a melting range of 58-62°C, was kindly donated by Paramelt (Heerhugowaard, 
Netherlands). Solvents of HPLC grade were purchased from Carlo Erba (Milan, Italy). 
2.2. Preparation of laminar extrudates 
The extrudates were prepared using a vertical lab scale ram extruder (Thalassia
®
, Trieste, Italy) 
described into details in a previous work (Grassi et al., 2003). Briefly, the movement of the stainless 
steel ram in this extruder is promoted by an oleodynamic cylinder driven by an electric pump (max 
pressure 150 bar). The cylindrical nickel plated brass barrel has a capacity of 66 cm
3
 and an internal 
diameter of 25 mm. The die attached at the end of the barrel can be changed on demand: in this case 
a rectangular die (with a flat entry, 0.5 mm x 5 mm cross section) was used. The barrel, acting as a 
powder reservoir, can be thermo-stated with an electrically heated jacket (max temp. ~ 120°C). In 
this case, based on previous experiences with analogous mixtures (Hasa et al., 2011), a temperature 
of 50°C was chosen. 
Prior to extrusion, the powdered materials (ternary mixtures of theo, lac and wax in different 
proportions according to Table 2) were mixed in 2.81 high shear mixer (Rotolab, Zanchetta®, 
Lucca, Italy) for 10 min at 120 rpm. Then, batches of 50 g of each mixture were packed to a 
constant volume into the barrel, by applying hand pressure, and equilibrated for 1 h at 50°C. Then, 
the mass was extruded through the rectangular die using a constant pressure. The laminar extrudates 
were collected and, after cooling at ambient temperature, were sliced up manually by use of a hot 
cutter in unities of length (7.5 mm) suitable to have a drug content for dissolution studies in sink 
conditions.  
At the end of the extrusion procedure, the samples were subjected to X-Ray Powder diffraction 
analysis in comparison to pure compounds and physical mixtures prepared in the same weight ratios 
to check the drug solid state in the samples. These data (not shown) attested that the drug still 
retains its crystalline state after extrusion, probably thanks to the high content of drug in the laminar 
extrudates and to the low extrusion temperature, below the melting point of the wax; thus the drug 
is neither amorphyzed nor molecularly dispersed into the carrier. The presence of the crystalline 
form of the active principle in the extrudates is in agreement with previous results  (Hasa et al., 
2011). 
2.3. Mixture experimental design 
Since the aim of the study was to analyze the influence of formulation composition on the in vitro 
drug release from the laminar extrudates, an experimental design approach for mixtures was applied 
for the planning of the extrusion experiments.  
On the basis of the preliminary trials, the component constraints were set for the percent amount of 
theophylline 55≤ x1≤65, lactose 5≤ x2≤15, and microcrystalline wax 28≤ x3≤32 to ensure that the 
experimental composition space contained feasible formulations with our operating conditions (e.g. 
laminar extrudates with a uniform surface and shape) and to obtain, at the same time, an extrudate 
with a probable in vitro sustained drug release. Due to the aim of the research, the response 
variables were the in vitro drug release from the prepared extrudates after 1 h (Y1) and after 8 h (Y2) 
tested at the conditions reported in the following paragraph 2.6. 
Table 1 summarizes the design of the optimization study and acceptance criteria for the drug 
release. 
The experimental plan (shown in Table 2 and Fig. 1), designed using NEMRODW software 
(Mathieu et al., 2002), consisted of 13 experimental runs (repeated in doubled experiments) and 6 
checkpoints. To reduce systematic errors experiments were completely randomized.  
2.4. Data analysis and validation of the optimisation model  
The special cubic model proposed by Scheffé (Scheffé, 1958; Lewis et al., 1999) was postulated to 
derive relationships between the responses (in vitro drug release at 1h and 8h) and mixture 
compositions, and to select an optimal extrudate formulation (Eq. 1) 
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According to the steps involved in the response surface methodology (RSM) (Voinovich et al., 
2009), after performing the mixture experiment by running every treatment combination given by 
the design and checkpoints, the coefficients of the experimental model were firstly estimated on the 
experimental data obtained by omitting the checkpoints. In this way, it was possible to validate the 
model by comparing the experimental data collected at the checkpoints with the corresponding 
response values calculated by the model. 
2.5. Robust optimization and reliability study 
In order to ensure a robust optimization, the desirability function approach (Derringer and Suich, 
1980) was also used. The desirability approach is one of the most applied methods whenever a 
compromise that best satisfies a set of predetermined objectives is searched for. The desirability 
function approach allows finding operating conditions for an optimal solution in two steps: 
1) transformation of every response as a function of the objectives under the form of an 
elementary desirability function (dj)  
),( objectivesYTd jjj           (2) 
2) creation of a global desirability function (D) characterizing the global compromise given by 
the geometric mean of the desirabilities 
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The desirability function estimates a percentage of compromise satisfaction. If a criterion value is 
not acceptable, the global desirability function is null, thus the compromise is rejected. Thanks to 
these transformations, at every point of the domain, the global desirability function can be 
calculated.  
Once the value of the responses at every point of the region of interest is determined (in validated 
models), every estimated response (Ycal,i) can be transformed to a value di representing the 
acceptance percentage of the value Ycal,i in relation to the fixed objectives (or desires) for the 
considered response. The calculation methods proposed for this transformation permit to obtain a 
percentage di so that 0%≤ di≤100%. If di =100%, the response Y1 calculated at this point is equal to 
its optimal value (called target value). On the contrary, if di = 0%, the response Y1 calculated at this 
point is over the tolerance limits. 
When the optimum of the D function is known, the composition that permits to best satisfy the 
constraints and the wideness of the optimal zone (corresponding to the space where the D function 
is possible) are determined. However, complementary information is required. It is necessary to 
know, inside the experimental domain of interest, what is the zone where the estimation of all the 
responses can be calculated with a probability ≤ α % of not respecting the fixed constraints for 
every response. 
 
2.6. Assay of drug content 
Samples of laminar extrudates were gently milled in a mortar with a pestle and dispersed in absolute 
ethanol and filtered (0.2 m, PES, Millipore Millex-HA). The concentrations of theophylline in the 
samples were measured using a previously described HPLC method (Voinovich et al., 2000). The 
percent drug content was compared to the calculated value. The experimental values were the mean 
values of three replicates. 
 2.7. In vitro release 
In vitro dissolution tests (conducted in triplicates) were performed under sink conditions (c ≤0.2 cs) 
using the USP rotating basket apparatus (Pharmatest, Steinheim, Germany), with a stirring rate of 
100 rpm, in 900 ml of purified water containing 0.1% polysorbate 20, thermostated at 37 ± 0.5°C. 
Slices of extrudates corresponding to 25 mg of theophylline were tested. The solution was filtered 
and continuously pumped (12.5 ml/min) to a flow cell in a spectrophotometer (UV2 Spectrometer, 
Unicam, Madison, WI). The amount of drug dissolved was analyzed at the maximum absorbance 
wavelength of the drug (271 nm). The results were reported as the mean values of three-replicated 
experiments and standard deviations were within 5% of the mean value. 
 
2.8. In vivo Studies 
For this experiment four healthy volunteers, aged between 25-55 years, and weighing on average 70 
kg were chosen. Before the analysis a written informed consent was signed by each subject. The 
research followed the tenets of the Declaration of Helsinki promulgated in 1964 and was approved 
by the institutional human experimentation committee. All the volunteers had normal hepatic and 
renal function. All subjects did not take any drug before and fasted from 12 h before drug 
administration until lunch on the treatment day. They were also asked not to take coffee or alcoholic 
beverages, nor smoking 12 h before and 24 h after the drug administration. The subjects were all 
given a standard lunch 6 h after the dosing, while were allowed to drink water during the treatment 
period. 
The dose (400 mg) of theophylline (corresponding to 16 slices of 7.5mm) was administered in 2 
type 00 hard gelatine capsules. Blood samples (5 ml) were drawn at 2, 4, 8, 12 and 24 h following 
capsule administration. Each sample was collected in a heparinised tube, and plasma was 
immediately separated by centrifugation (at 5000 g for 15 min), subsequently frozen and stored at -
20°C until assayed.  
2.9. Sample analysis 
The concentrations of theophylline in the plasma samples were measured using a previously 
described HPLC method (Voinovich et al., 2000). 
 
2.10. Pharmacokinetic analysis 
Individual plasma concentration-time profiles were analyzed by non-compartmental 
pharmacokinetic analysis using WinNonlin version 2.1 (Pharsight, Mountain View, CA, USA). 
Maximum plasma concentration (Cmax) and corresponding sampling time (tmax) were recorded as 
observed. Half-life of the terminal phase (t1/2,z) was calculated as the natural logarithm of 2 divided 
by the slope (z) of the linear regression line of the terminal log-linear portion of the concentration-
time curve. Area under the plasma concentration curve from time 0 to the last measured 
concentration at 24 h (AUC24) was calculated by the linear trapezoidal rule and extrapolated to 
infinite time (AUC∞) by addition of the term C(24)/z, where C(24) is theophylline plasma 
concentration at 24 h. Mean residence time (MRT) was calculated as AUMC/AUC, where AUMC 
is the area under the first moment curve. 
 
2.11. In vitro/ in vivo mathematical modelling 
The in vitro and the in vivo data were analysed by a previously presented mathematical model that 
relies on the following assumptions (Hasa et al., 2011): 
1) drug pharmacokinetics can be represented by a two-compartments model with first order 
elimination in the blood, 2) drug release kinetics in the G.I. fluids is not affected by the absorption, 
metabolism and gastrointestinal transit and it can be replaced by the in vitro release kinetics and 3) 
the drug concentration in the central compartment (blood plasma) (Cc) can be always retained 
negligible in comparison to the drug concentration in the gastrointestinal fluids (CGI). Accordingly, 
model equations read: 
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where t is time, R(t) represents the drug release kinetics coincident with that measured in vitro; Vc 
and VGI are the volumes of the central (blood plasma) and gastrointestinal G.I. compartments, 
respectively; kel and kab are, respectively, the elimination and the absorption rate constants; A is the 
G.I. tract geometrical surface (i.e. that not accounting for the presence of villi and microvilli that is 
considerably higher); P is G.I. apparent permeability, kcp and kpc are distribution rate constants from 
the central to the peripheral compartment, respectively; f is the ratio between volumes of the central 
(Vc) and peripheral (Vp) compartments; and Cp indicates drug concentration in the peripheral 
compartment (tissue). 
Eqs. (4)-(6) differ from the usual expression of pharmacokinetic equations (Holz and Fahr, 2001) 
for the assumption that drug distribution among blood and tissues is ruled by drug concentration 
instead of by drug mass. This leads to the introduction of parameter f that renders the model more 
physiologically oriented as it allows differentiating the extension of blood and tissue volumes. It is 
worth noticing that when f = 1, this approach and the traditional one (Holz and Fahr, 2001) coincide. 
In addition, when kcp is set to zero, Eqs. (4)-(6) represent the simpler one compartment 
pharmacokinetics model. R(t) is determined assuming that in vitro release kinetics can be properly 
fitted by a sum of m exponential functions: 
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where m, Ai and ki are parameters to be determined by fitting eq.(7) to the in vitro release data and 
M0 is the drug dose. Insertion of eq.(8) into eq.(4) assuming that CGI = Cc = Cp = 0 when t = 0, leads 
to model analytical solutions: 
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3. Results and Discussion 
In this optimization study a mixture experimental design in a constrained region of interest was 
used to estimate the model coefficients in Eq. (1) in order to represent and analyze the response 
surfaces obtained on the basis of the experimental trials on the formulations. The experimental 
results (expressed as mean values) along with the standard deviations (SD) are reported in Table 2. 
The special cubic models fitted to the experimental data (checkpoints included after model 
validation) along with the adjusted R
2
 are given in Table 3. It is worth of note that the calculated 
responses, y1 and y2 are expressed in terms of the percentages of the pseudocomponents Xi. 
For the comparison of the two response surfaces reported in Table 3, the corresponding contour 
plots are shown in Fig. 2.  
In order to attain a robust optimization for the drug release, it was required to be very close to a 
desired value - the target value - in this case 35% for the release after 1 hour and 75% for the 
release after 8 hours (Fig. 3). A desirability function approach was therefore used. For this 
desirability study, the objectives were expressed by the following limits for the two responses here 
considered: 
            30% ≤ Y1≤ 40%   
70% ≤ Y2≤ 80%                 (15) 
The best solution identified for the formulation is given in Table 4 along with desirability functions 
for the optimisation, di ( ) the partial desirability and the D the overall desirability. The optimal 
experimental conditions are expressed both in terms of pseudocomponents  and as original 
components. In Fig. 4 (top) the variation of the desirability function is graphically represented.  
For a robust optimization the desirability function was further assessed and optimized in terms of 
reliability. The purpose was to identify the zone where the estimation of all responses can be 
calculated with a probability ≤ α % of not respecting the fixed constraints for every response. For 
the two responses under study it was imposed that:  
Prob[(30% < Y1 < 40%]  ≥ 0.80  
Prob[(70% < Y2 < 80%] ≥ 0.80.     (16) 
Thanks to the respect of the constraints with a probability ≥ (1- α), the optimal zone was reduced 
with the distinction of two limited areas (Fig. 4, bottom). These two areas were further analysed in 
order to define the composition space that ensures the quality of the final product. The allowable 
operational flexibility in the ternary formulation (theophylline:lactose:wax) for the two areas are 
summarized in Table 5. 
In Fig. 5 the composition spaces (delimited by the black triangles) are displayed along with the 
tested formulations with the mixture design (black circles).  
While the A area was very small and in proximity to the lower boundary, inside the B area the 
formulation theophylline:lactose:wax, 57:14:29 (%) was selected to be used for the in vivo studies. 
This formulation guaranteed an in vitro drug release of 33% after 1h (Y1), and of 76% after 8h (Y2) 
(Fig. 6). 
The in vitro performance of this formulation was also analysed by a previously presented 
mathematical model (Hasa et al., 2011). Release kinetics model Eq.(8) was fitted to the observed in 
vitro release data (Fig. 6). The model was in very good agreement with the observed data (F(2, 177, 
0.95) < 16903) and the estimated parameters (A1, k1, k2) values were A1 = (0.66 ± 0.003), k1 = (0.128 
± 0.001) h
-1
, A2 = 1 - A1 and k2 = (1.23 ± 0.05) h
-1
. Accordingly, in vitro release kinetics could be 
described by a slow (A1, k1) and a fast (A2, k2) component being the slow component the prevailing 
one. Fig. 6 shows the in vitro release kinetics predicted by Eq.(8) in the hypothesis that only the 
slow (dotted line; A1 = 1, A2 = 0, k1 = 0.128 h
-1
) or only the fast (solid thick line; A1 = 0, A2 = 1, k2 = 
1.23 h
-1
) component rules the release kinetics. In the first case, the fractional drug release 
(100*Mt/M∞) is not complete within the experimental time (500 min) while, in the second case, the 
release process is almost complete after 200 minutes. 
Bioavailability parameters are reported in Table 6. These results demonstrate that the selected 
formulation behaves as a sustained release formulation. Comparison of the observed AUC value 
with the AUC value of the commercial sustained release formulation of theophylline (Henrist et al., 
1999) indicates a trend of improved bioavailability. The observed values of t1/2,z were higher than 
the reported theophylline elimination half-life of 6 to 10 h (Jonkman et al., 1989), indicating a flip-
flop phenomenon. The rate of absorption was therefore manifested in the terminal slope of the 
concentration-time curve. In vivo behaviour of the tested formulation was similar to the previously 
evaluated experimental sustained release cluster matrix tablets containing hydrophobic wax and 
hydrophilic polymer granules (Hayashi et al., 2007). 
Parameters of the in vitro release model Eq.(8) (A1, k1, A2, k2) and theophylline pharmacokinetics 
parameters determined elsewhere (Hasa et al., 2011) (Vc = 19.3 l, f = 1, kel = 0.12 h-1, kab = 0.13 h-1, 
kcp = 2.7 h
-1
, kpc = 2.9 h
-1
, M0 = 400 mg, Vr = 300 ml), were used for simulation of concentration. 
The simulation of Eq.(10) was in good agreement with the experimental theophylline plasma 
concentration-time course as shown in Fig. 7. Indeed, this prediction falls within the standard 
deviation associated with the concentration data up to 12 h, while there is minor discrepancy with 
the final concentration measurement at 24 h. It is interesting to notice (see Fig. 7) the considerable 
variation of the predicted plasma concentration when only the fast (solid thin line) or only the slow 
(dotted line) are considered for the description of the release phenomenon (see eq.(5) and (6)). This 
witnesses the importance played by a proper designing of the release process. 
Conclusion 
This study attested that laminar melt extrusion is a suitable technique for the production of a novel 
oral retard formulation with a precise drug release over time. The application of the experimental 
design for mixtures, associated to a desirability function, permitted to define the robustness of the 
formulation by defining acceptable quality of the product. 
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1. Legends for Figures 
2. Fig. 1. The constrained experimental region in the three-component system given by the 
restrictions on the component proportions 0.55≤ X1≤0.65,  0.05≤ X 2≤0.15 and 0.28≤ X 
3≤0.32; black dots represent experimental points. 
3. Fig. 2. Contour plot for Y1 (top) and Y2 (bottom) in the constrained experimental region. 
4. Fig. 3. Desirability function for the two studied experimental responses: Y1 (top) and Y2 
(bottom). 
5. Fig. 4. Contour plot of desirability function before (top) and after the reliability study (bottom). 
6. Fig. 5. Optimal composition spaces (delimited by black triangles) for the two considered 
response variables, along with the tested formulations (black circles). 
7. Fig. 6. Eq.(7) best fitting (solid thick line) to experimental in vitro release data (open circles; 
vertical bars indicate standard deviation). Dotted and solid thin line indicate, respectively, 
eq.(7) prediction about the release kinetics assuming that only the slow (A1 = 1, k1 = 0.128 
h-1) or the fast (A2 = 1, k2 = 1.23 h-1) release component rules the drug delivery. t is time 
while Mt/M∞ indicates the fractional release. 
Fig. 7. Comparison between the experimental theophylline plasma concentration (filled circles; 
vertical bars indicate standard deviation) and eq.(9) prediction (solid thick line) assuming 
the parameters (A1 = 0.66, k1 = 0.128 h-1, A2 = 0.34, k2 = 1.23 h-1) coming from eq.(7) 
best fitting to in vitro release data (see Fig. 6) and the theophylline pharmacokinetics 
parameters elsewhere determined (Hasa et al., 2011) (Vc = 19.3 l, f = 1, kel = 0.12 h-1, kab 
= 0.13 h-1, kcp = 2.7 h-1, kpc = 2.9 h-1, M0 = 400 mg, VGI = 300 ml). The dotted and the 
solid thin line indicate, respectively, eq.(9) prediction assuming that only the slow (A1 = 1, 
k1 = 0.128 h-1) or the fast (A2= 1, k2 = 1.23 h-1) release component rule the drug delivery. 
t is time while Cc indicates the theophylline plasma concentration.

 
 
 
 
Table 1. Design of the mixture study for the drug release optimization.  
Associated 
variable 
Factors: formulation components Lower limit 
% 
Upper limit 
% 
x1 theophylline  55 65 
x2 monohydrate lactose 5 15 
x3 microcrystalline wax 28 32 
 Responses Target values 
   
y1 Drug release after 1 hour 35% 
y2 Drug release after 8 hours 75% 
 
 
Table 2. Design point coordinates in the constrained region inside the factor space given by three 
blend components, along with experimental results (two replications for experiments 1 to 13). 
 Formulation factor (%) Experimental response (%) 
 
Design points x1 x 2 x 3 y1 y2 
1 55.0 13.0 32.0 23.0, 25.0  67.0, 70.0 
2 65.0 7.0 28.0 31.0, 33.0 73.0, 78.0 
3 55.0 15.0 30.0 27.0, 29.0 74.0, 69.0 
4 57.0 15.0 28.0 35.0, 38.0 81.0, 83.0 
5 65.0 5.0 30.0 24.0, 21.0 64.0, 67.0 
6 63.0 5.0 32.0 20.0, 17.0 72.0, 68.0 
7 55.0 14.0 31.0 23.0, 26.0 69.0, 70.0 
8 59.0 9.0 32.0 21.0, 17.0 71.0, 70.0 
9 61.0 11.0 28.0 34.0, 36.0 84.0, 80.0 
10 65.0 6.0 29.0 27.0, 30.0 71.0, 73.0 
11 56.0 15.0 29.0 32.0, 37.0 76.0, 73.0 
12 64.0 5.0 31.0 21.0, 22.0 68.0, 70.0 
13 60.0 10.0 30.0 26.0, 24.0 78.0, 77.0 
14* 57.5 11.5 31.0 26.0 70.0 
15* 62.5 8.5 29.0 30.0 73.0 
16* 57.5 12.5 30.0 26.0 71.0 
17* 58.5 12.5 29.0 35.0 75.0 
18* 62.5 7.5 30.0 25.0 71.0 
19* 61.5 7.5 31.0 23.0 74.0 
*checkpoints  
 
 
Table 3.  Response models and statistical data obtained from ANOVA after the model validation 
step  
Response Special cubic model Adjusted 
R
2
 
Significance 
y1 30.29𝑋1+37.55𝑋2+16.83𝑋3+6.46𝑋1𝑋2-32.39𝑋1𝑋3    
-35.57𝑋2𝑋3-39.28𝑋1𝑋2𝑋3 
0.88 <0.01*** 
y2 69.00𝑋1+78.03𝑋2+11.43𝑋3+34.12𝑋1𝑋2-59.96𝑋1𝑋3   
-92.92𝑋2𝑋3-36.91𝑋1𝑋2𝑋3 
0.76 <0.01*** 
Significance code (α): *** p= 0.001 (0.1%) 
 
Table 4. Optimal experimental conditions and predicted responses 
Pseudocompomponents  Original components Predicted properties  Desirability (di) 
X1= 0.09 Theophylline = 0.56 y1= 33 % d1 (𝑦 1)= 82.52 
X2 = 0.83         Lactose = 0.15 y2= 76%    d2 (𝑦 2)= 62.96 
X3 = 0.08               Wax = 0.29   D = 72.08 
 
Table 5. Allowable operational flexibility in the ternary formulation (%) for the two areas. 
Area A Area B 
63.2 < Theophylline <63.5 57.1 < Theophylline < 57.7 
8.3 < Lactose <8.6 13.6 < Lactose <14.2 
28.2 < Wax < 28.5 28.7 < Wax < 29.3 
 
 
Table 6. Bioavailability parameters after oral administration of 400 mg of theophylline as an 
experimental sustained release formulation to four healthy subjects.  
Parameter Mean (SD) 
tmax (h) 5.00 (3.46) 
Cmax (mg/l) 6.94 (0.77) 
AUC24 (mg h/l) 106.5 (13.6) 
z (h
-1
) 0.0653 (0.0087) 
t1/2,z (h) 10.77 (1.56) 
AUC∞ (mg h/l) 140.3 (27.1) 
MRT (h) 17.0 (3.2) 
 
 
 
 
